Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced that Dr. Christian Homsy, Chief Executive Officer, will present and participate in a panel discussion at the upcoming Gene and Cell Therapy Meeting on the Mesa being held October 5-7, 2016 in La Jolla, CA, USA.
Dr. Homsy will present during the Partnering Forum event on Wednesday, October 5, 2016 at 11:15 a.m. Pacific Time. He will discuss Celyad’s recent developments and clinical progress of the engineered T-cell product candidate, NKR-2, for the treatment of cancer.
Dr. Christian Homsy, CEO of Celyad, commented, “I am excited to present our unique natural killer receptor T-cell asset and participate in the panel discussion at Meeting on the Mesa, one of the preeminent conferences in our industry. I look forward to sharing the stage with fellow leaders in the CAR-T field to discuss some of the opportunities and challenges facing our industry.”
Organized by the Alliance for Regenerative Medicine (ARM) and the Sanford Consortium for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference bringing together senior executives from the cell and gene therapy and the scientific communities to discuss the most pressing issues facing the sector.